Introduction
============

We live in a period where molecular biology is being widely and effectively applied in every field of medicine. Technical advances have led to the development of new molecular mechanism-based target drugs for several diseases. In the field of pediatric neurosurgery, the causative genes for some diseases have been identified, and this information has enabled genetic diagnosis and improved disease classifications.

Diseases treated by pediatric neurosurgeons, including the various forms of hydrocephalus, can be classified according to the available molecular genetics knowledge base, and its clinical applications, as follows. In the first group, genetic testing has been clinically established and is already used in disease diagnosis, disease classification, carrier detection, and prenatal diagnosis. In the second group, the molecular cause has not been firmly established and clinical tools are not yet available, but some causative genes have been identified, and/or there are recent molecular findings regarding the pathophysiology and classification. In the third group, the molecular basis of the disease is still uncertain, and the clinical significance of current research findings has not been established.

Of hydrocephalus and its related diseases, X-linked hydrocephalus (XLH) is categorized in the first group, holoprosencephaly (HPE) and porencephaly in the second, and Dandy--Walker syndrome and myelomeningocele in the third.

XLH
===

XLH was first described by Bickers and Adams in 1949, as HSAS, the acronym for [**H**]{.ul}ydrocephalus due to [**S**]{.ul}tenosis of the [**A**]{.ul}queduct of [**S**]{.ul}ylvius (MIM 307000).^[@B1]^ Since the first family of XLH carriers with a gene mutation in neural cell adhesion molecule L1CAM (L1) was reported in 1992,^[@B2]^ there have been many advances in the genetics of XLH. L1 is a member of the immunoglobulin (Ig) superfamily of cell adhesion molecules, and is expressed predominantly in developing neurons. Mutations in the *L1* gene were found to be responsible for many cases of XLH, mental retardation, adducted thumbs, shuffling gait and aphasia (MASA) syndrome, certain forms of X-linked spastic paraplegia (SPG1), and X-linked agenesis of the corpus callosum (ACC). Therefore, these syndromes have been reclassified and grouped together as L1 syndrome.^[@B3]^

The *L1* gene is located on the X chromosome in humans, and is composed of 28 exons. The open reading frame has 3,825 base pairs (bps), and encodes a protein of 1,257 amino acids. According to an updated (May, 2014) database of *L1* gene mutations (web site maintained by Yvonne Vos from the Department of Genetics, University Medical Center Groningen, Groningen), 211 mutations have been found in 254 unrelated families with L1 syndrome.^[@B4]--[@B6]^ In Japan, Kanemura et al. conducted a nation-wide investigation of *L1* gene mutations and identified *L1* mutations in 90 unrelated families.^[@B7]^

The sites and types of the *LI* gene mutations in families with XLH are almost always different, regardless of race. Genotype and phenotype correlations have been reported.^[@B8],[@B9]^ Yamasaki et al. revealed a striking correlation between the mutation class and the severity of ventricular dilatation. Class I mutations affect only the cytoplasmic domain (CD) of L1. Class II mutations consist of missense point mutations and deletions in the extracellular domain (ED) that result in a predicted protein that should remain associated with the plasma membrane. Class III mutations include nonsense or frame-shift mutations that produce a premature stop codon in the L1ED. The mutant molecules in this class do not remain associated with the cell membrane and therefore lose all the normal functions of L1. Mutations in the non-coding region are divided into splice-site mutations and others. Splice-site mutations result in the same L1 protein structure as Class III mutations and cause loss of function.^[@B10]^

Class II mutations can be divided into two subclasses based on molecular modeling studies. One subgroup includes mutations affecting the key residues in L1ED that are responsible for maintaining the conformation of the domains, and the other subgroup includes mutations that affect residues on the protein's surface.^[@B11]^ Patients whose ventricles showed severe dilatation had Class III mutations, exon 1--26 splice-site mutations, or Class II L1ED key-residue mutations. All of these mutations cause the loss of L1ED function, and are therefore referred to as L1-LF mutations.

All of the patients with L1-LF mutations had severe ventricular dilatation ([Fig. 1a](#F1){ref-type="fig"}), required a ventriculoperitoneal (VP) shunt in the early days of life; however, most of these patients show severe developmental delays, including lack of independent locomotion and an undetectably low intelligence quotient (IQ). To look at the characteristics of radiological findings, they showed a rippled ventricular wall after shunting ([Fig. 1b](#F1){ref-type="fig"}), which is not seen in other kinds of hydrocephalus, and is an absolute characteristic of the severe hydrocephalus that accompanies L1-LF mutations. This unique neuro-radiological finding can be used as one of the clinical diagnostic criteria of XLH with an L1-LF mutation.

Notably, most of the patients with L1-LF mutations also had an enlarged massa intermedia, enlarged quadrigeminal plate, and hypoplasia of the cerebellar vermis ([Fig. 1c](#F1){ref-type="fig"}). These results are consistent with reported pathological findings of XLH, which include an enlarged massa intermedia or fused thalami ([Fig. 1c](#F1){ref-type="fig"}). Hypoplasia of the cerebellar vermis has also been reported in XLH patients^[@B12]^ and observed in L1-knockout mice.^[@B13]^

There are two possible explanations for the ventricular dilatation caused by *L1* mutations. First, a decrease in elasticity in the white matter might increase the vulnerability of the ventricular system to alteration by cerebrospinal fluid (CSF) pressure. Second, maldevelopment of the midline structure might cause narrowing of the CSF pathway. Both mechanisms may be at work, and both are compatible with the loss of L1 functions, such as L1-mediated cell adhesion and cell migration, being responsible for the ventricular dilatation.

These characteristic radiological findings could be explained by a decrease in white-matter elasticity, resulting from the loss of axons and axon adhesion, which could also explain the rippled appearance of the ventricular wall. In addition, maldevelopment of the midline structure could be induced by the disturbance of L1-mediated cell migration, which could cause the enlargement of the massa intermedia and quadrigeminal plate. In support of this mechanism, Kamiguchi et al. reported *in vitro* findings that neuronal migration from the subependymal zone in the songbird brain depends on a heterophilic interaction between neuronal L1 and a radial glial cell receptor.^[@B14]^ The enlarged massa intermedia would cause narrowing of the third ventricle, and the enlarged quadrigeminal plate would cause narrowing of the aqueduct.

*L1* genetic testing has been clinically established and is already used in prenatal and postnatal diagnosis of the disease and in carrier detection.^[@B15]^ Renier reported that XLH shows the poorest outcome of any prenatal non-communicating hydrocephalus.^[@B16]^ For a mother carrying an *L1* mutation, 50% of the male fetuses could have severe hydrocephalus; therefore, prenatal molecular genetic diagnosis with genetic counseling is extremely beneficial for a family with XLH. The prenatal molecular genetic diagnosis of L1 syndrome was first reported by Jouet et al. in 1995.^[@B17]^

Later, prenatal L1 gene analysis was systematically organized by Yamasaki et al.^[@B15]^ In 2003, new clinical guidelines for genetic testing were established by 10 Japanese genetic-medicine-related societies (Guideline 2003). This guideline recommends that carriers be tested voluntarily with informed consent, which means that carrier testing in childhood is prohibited. Therefore, since the release of Guideline 2003, only male fetuses have been tested. Nine obligate carriers have requested prenatal testing a total of 14 times.^[@B15]^ The fetuses were tested for sex, *L1* mutation, or both using chorionic villus sampling (CVS) or amniocentesis (AC). Of the 14 fetuses, 4 were male and 10 were female. Prenatal genetic testing was performed on seven of the fetuses, three females (prior to 2003) and four males. Of the four male fetuses tested, only one had an *L1* gene mutation. The mother terminated the pregnancy. In 13 of the 14 cases, the mothers continued their pregnancies, and delivered healthy babies that lacked an XLH phenotype. Thus, the diagnoses were made with perfect accuracy. In 12 of the 14 cases, DNA was obtained by CVS between 10 weeks and 12 weeks gestation, and in two it was obtained by AC between 15 weeks and 16 weeks gestation. No maternal or fetal complications occurred during either CVS or AC.^[@B15]^

HPE
===

HPE was once thought to be caused by an abnormal separation of the prosencephalon occurring after the completion of neural tube closure. However, molecular genetic research revealed that HPE starts before closure of the neural tube and is associated with a molecular abnormality manifested at the prochordal plate during the preneurulation period. Neural differentiation abnormalities caused by a mesenchyme defect are thought to lead to a lack of separation of the left and right cerebral hemispheres, resulting in various symptoms.^[@B18]^ DeMyer's classical classification of HPE into three types---the alobar ([Fig. 2](#F2){ref-type="fig"}), semilobar, and lobar types---according to the degree of unseparation between the left and right cerebral hemispheres, is still used today.^[@B19]^

The incidence of HPE was previously reported as 1 in 10,000 births, because although it occurs in 1 in 250 pregnancies, only 3% of the affected fetuses are delivered. In the West Midland Congenital Abnormality Register WMCAR), for which the data were collected in 1995--2004, after the technology for prenatal diagnosis was established, the incidence is reported as 1.7 in 10,000 births, essentially the same as reported previously. HPE is rarest among whites and most common among Africans and Pakistanis.^[@B20]^

Environmental and genetic factors are interrelated, and both contribute to HPE. One report maintains that maternal diabetes is an important risk factor, increasing the frequency of HPE 100-fold. Other factors are alcohol, anticonvulsant drugs, retinoic acid, smoking, fetal cytomegalovirus infection, and hypocholesterolemia. The relationship between HPE and cholesterol has been studied. Patients with Smith-Lemli-Opitz syndrome, a common complication of HPE, have a defect in 7-dehydrocholesterol reductase, which is involved in cholesterol metabolism. Cholesterol is necessary to activate the sonic hedgehog (Shh) signaling pathway, the malfunction of which is thought to cause HPE.^[@B21]^

Chromosomal abnormalities are seen in 40--45% of HPE cases. The chromosomal abnormalities include trisomy 13 and trisomy 18, but trisomy 13 is the most common, accounting for 30--70% of the chromosomal abnormalities in reports on HPE Cases with known chromosomal abnormalities are classified as HPE 1 to HPE 12. In addition, there are 16 known HPE-associated genes, and the causal genes for HPE2--5,7,9,10,11 and 12 have been identified ([Table 1](#T1){ref-type="table"}). Of the 16 known HPE-associated genes, mutations are found most often in *SHH, ZIC2, SIX3,* and *TGIF*. A genetic study of 205 patients with HPE revealed *SHH* mutations in 47 (23%)*, ZIC2* mutations in 88 (43%)*, SIX3* mutations in 59 (29%), and *TGIF* mutations in 11 (5%).^[@B22]^

A mutation in *SHH* was first identified as a cause of HPE in 1996.^[@B23]^ *SHH* encodes Shh, a secreted protein that is a key inductive signal for ventral patterning of neural tube. Since then, many genes for Shh signaling components have been shown to bear HPE-associated mutations. Of the patients with *ZIC2* mutations, almost 90% have a structural brain anomaly. Patients with *SIX3* mutations are most likely to have an alobar type of brain anomaly. However, in the study of 205 patients described above, 44 relatives who were phenotypically normal also had mutations in *SHH, ZIC2, SIX3,* or *TGIF*. Therefore, more genotype and phenotype correlation studies are needed to improve the genetic analysis of HPE for clinical applications.^[@B24]^

Notably, however, only about 5--10% of HPE cases are due to mutations in established HPE genes, and 30--50% of HPE cases are due to a chromosomal anomaly, including deletions and duplications. Therefore, a comprehensive cytogenetic study of patients with HPE should begin with a high-resolution karyotype. Finally, for nonsyndromic HPE patients and those without a chromosomal abnormality, a molecular analysis of the most common implicated genes (*SHH, ZIC2,* and *SIX3*)^[@B25]^ should be performed*.*

Dandy--Walker Malformation (DWM)
================================

DWM is a congenital disease whose features are aplasia or dysplasia of the cerebellar vermis, a midline cyst connecting with the IVth ventricle, and elevation of the tentorium, torcular herophili, and transverse sinus ([Fig. 3](#F3){ref-type="fig"}). Epidemiologically, DWM occurs with a frequency of one in 25,000--35,000 births, and according to a nationwide survey in Japan, with equal frequency in both sexes.

The etiology of DWM is unknown, but one well-accepted idea is that it is caused by the suspension of rhombencephalic development, accompanied by dysraphism of the cerebellum at the midline. DWM is accompanied by more than 18 types of chromosomal abnormality; for example, abnormalities of 2q, 5p, 8p, 9p, 13q, 16q, and 17q are reported. More than 40 genetic syndromes co-occur with DWM. In addition, DWM can arise as a result of maternal diabetes, maternal use of warfarin, or fetal infection by cytomegalovirus or rubella.

Recently, two important loci, 3q24 and 6q25.3, were identified as causative areas of DWM. In these areas, *ZIC1* and *ZIC4* located in 6q25.3 and *FOXC1* in 3q24 were found to be important genes. More than 10 cases of DWM with deletions in 6q25.3, including the *ZIC1* or *ZIC4* gene, have been identified.

Neural Tube Defect (NTD)
========================

NTD is a situation in which the closure of neural tube does not occur properly. When it occurs in the caudal portion of the neural tube, it becomes a myelomeningocele. Tissues that normally cover the dorsal spinal cord, such as the meninges, the dorsal part of the spinal arch, and the skin do not form, causing the neural placode to be exposed dorsally. Of myelomeningocele cases, 80--90% are accompanied by hydrocephalus, requiring treatment.

It has been discovered that disruption of the planar cell polarity (PCP) signaling pathway causes NTD in mice. The PCP signaling pathway is important for the uniform orientation of cell polarity in tissues. The NTD phenotype of a classic mutant mouse, Looptail, is caused by a mutation of the PCP gene *Vangle2*. Recently, PCP genes were strongly implicated as causal in human NTDs. Single-nucleotide variants, predominantly heterozygous missense genomic alterations, have been found in the coding region of the core PCP genes *CELSR1*, *FZD6*, *PRICKLE1*, *DVL2*, *VANGL1,* and *VANGL2* of patients with NTD.^[@B26]^ PCP signaling is also essential for the directional beating of motile cilia. The apical surface of ependymal cells of the cerebral ventricle is covered with cilia, whose beating facilitates the circulation of CSF. Tissir et al. reported that PCP-related cadherins *Celsr2* and *Celsr3* control this process. *Celsr2*-deficient mice develop defective CSF dynamics and hydrocephalus.^[@B27]^ *Celsr2* and *Celsr3* double mutants show impaired ciliogenesis, resulting in lethal hydrocephalus. Therefore, PCP genes are now among the genes investigated as likely candidates for the molecular basis of hydrocephalus and hydrocephalus-related disease.

Conclusion
==========

Hydrocephalus and hydrocephalus-related diseases are considered to be multifactorial diseases, caused by both genetic and environmental factors. For single gene disorders like XLH, clinical genetic testing is already available. For these diseases, future research will focus on developing therapies based on their molecular mechanisms. On the other hand, while genetic factors are mainly responsible for HPE and DWM, these diseases involve interactions of multiple genes and their phenotypes are heterogeneous. The molecular biology of these disorders is still not fully understood. The role of PCP genes in the genesis of hydrocephalus is becoming clear, although more analysis is needed before we can fully understand the molecular biology in detail and develop appropriate clinical applications.

![X-linked hydrocephalus with *L1* gene mutation. a: MRI (T~1~) shows severe ventricular dilatation. b: MRI (T~2~) after VP shunt shows rippled ventricular wall. c: MRI (T~2~) shows an enlarged massa intermedia (![](nmc-55-640-i1.jpg)) anterior vermis hypoplasia (←), and a large quadrigeminal plate (⇒), callosal dysplasia was observed (![](nmc-55-640-i2.jpg)). MRI: magnetic resonance imaging, VP: ventriculoperitoneal.](nmc-55-640-g1){#F1}

![Fetal magnetic resonance imaging of the patient with 13 trisomy shows alobar type holoprosencephaly.](nmc-55-640-g2){#F2}

![Magnetic resonance imaging (T~1~) after birth shows Dandy--Walker malformation.](nmc-55-640-g3){#F3}

###### 

Causative genes of hydrocephalus

  HPE              Location of chromosome   Casusal genes            Authors                                   References^[@B23],[@B24]^
  ---------------- ------------------------ ------------------------ ----------------------------------------- --------------------------------------------------
  HPE2             2p21                     *SIX3*                   Wallis DE                                 *Nature Genet* 22: 196--198, 1999
  HPE3             7p36                     Sonic hedgehog (*SHH*)   Roessler E                                *Nature Genet* 14: 357--360, 1996
  HPE4             18p11.3                  *TGIF1*                  Gripp KW                                  *Nature Genet* 25: 205--208, 2000
  HPE5             13q32                    *ZIC2*                   Brown SA                                  *Nature Genet* 20: 180--183, 1998
  HPE7             9q22.3                   *PATCHED-1*(*PTCH1*)     Ming JE                                   *Am J Hum Genet* 71: 1017--1032, 2002
  HPE9             2q14                     *GLI2*                   Roessler E                                *Proc Natl Acad Sci USA* 100: 13424--13429, 2003
  HPE10            1q42                     *DISP1*                  Roessler E                                *Hum Genet* 125: 393--340, 2009
  HPE11            11q24.2                  *CDON*                   Bae GU                                    *Am J Hum Genet* 89: 231--240, 2011
  HPE12            6q27                     *DLL1*                   Dupe V                                    *Hum Mol Genet* 20: 1122--1131, 2011
  3p21--p23        *TDGF1*                  De la Cruz JM            *Hum Genet* 110: 422--428, 2002           
  6q22.31--q23.2   *EYA4*                   Abe Y                    *Hum Mutat* 30: E946--E955, 2009          
  8q24.3           *FAST1*(*FOXH1*)         Cohen MM Jr              *Am J Med Genet* 123A: 5--28, 2003        
  9q21.33          *GAS1*                   Ribeiro LA               *Am J Med Genet* 152A: 1688--1694, 2010   
  10q22.4          *NODAL*                  Roessler E               *Mol Genet Metab* 98: 225--234, 2009      
  10q24            *FGF8*                   Arauz RF                 *Mol Syndromol* 1: 59--66, 2010           
  11q13.4          *DHCR7*                                                                                     
  HPE1             21q22                                                                                       
  HPE6             2p37.1                                                                                      
  HPE8             14q13                                                                                       

HPE: hydrocephalus.
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